Atria Investments Inc Sells 647 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Atria Investments Inc cut its position in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 25.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,927 shares of the company’s stock after selling 647 shares during the quarter. Atria Investments Inc’s holdings in BeiGene were worth $433,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BGNE. Price T Rowe Associates Inc. MD grew its stake in BeiGene by 6.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after purchasing an additional 117,905 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in BeiGene in the 2nd quarter valued at $54,412,000. TD Asset Management Inc increased its stake in shares of BeiGene by 1.4% in the 2nd quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock valued at $16,318,000 after purchasing an additional 1,599 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of BeiGene by 33.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 110,000 shares of the company’s stock valued at $15,694,000 after purchasing an additional 27,857 shares during the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of BeiGene by 8.9% in the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after purchasing an additional 7,816 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors.

BeiGene Stock Performance

Shares of BGNE opened at $194.26 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The stock has a 50 day moving average price of $212.60 and a two-hundred day moving average price of $182.77. The firm has a market capitalization of $18.92 billion, a P/E ratio of -23.58 and a beta of 0.63. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.01 earnings per share. Equities analysts forecast that BeiGene, Ltd. will post -5.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Chan Henry Lee sold 1,202 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,070 shares of company stock valued at $4,901,050. Corporate insiders own 7.43% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on BGNE. JPMorgan Chase & Co. boosted their price objective on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. Citigroup boosted their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. StockNews.com downgraded BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday. TD Cowen upped their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, JMP Securities started coverage on BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and an average price target of $247.07.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.